Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS‐0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner‐Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women's Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.